+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adult Vaccines Market - Global Forecast 2026-2032- Product Image
Adult Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Adult Vaccines Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6015023
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Adult Vaccines Market is projected to reach USD 22.58 Billion in 2026. It is expected to continue growing at a CAGR of 8.46%, reaching USD 36.68 Billion by 2032.

Adult Vaccines: Executive Overview

Adult vaccination is an established public-health intervention spanning routine immunization, catch-up programs, occupational protection, travel health, and vaccination of people at elevated clinical risk. Demand is shaped by aging populations, chronic disease prevalence, exposure risk, evolving immunization schedules, and government efforts to reduce preventable illness across the life course.

How Adult Immunization Is Changing

The landscape is shifting from predominantly pediatric immunization toward life-course vaccination. Programs increasingly emphasize older adults, pregnant people, healthcare workers, travelers, and individuals with underlying conditions. Delivery is also moving beyond specialist settings through pharmacies, primary-care practices, workplaces, community clinics, and digital appointment systems. Greater attention to equity, convenience, cold-chain resilience, and public trust is influencing how adult vaccination programs are designed and delivered.

Artificial Intelligence Strengthens Adult Vaccine Delivery

Artificial intelligence can support adult immunization by identifying people who are overdue, improving outreach prioritization, forecasting appointment demand, and helping health systems optimize inventory and clinic capacity. Natural-language tools can assist with patient education and multilingual communication, while analytics can help identify gaps by age, risk status, geography, and socioeconomic factors. Effective use requires validated data, privacy safeguards, clinical oversight, transparent decision criteria, and monitoring for bias so that automation improves access rather than reinforcing existing disparities.

Regional Priorities Across Adult Vaccination

North America is characterized by broad adult recommendations, pharmacy-based delivery, and strong attention to seasonal and risk-based vaccination. Latin America continues to balance expanding adult coverage with differences in financing, access, and health-system capacity. Europe combines national immunization policies with European Union coordination, while priorities include healthy aging, high-risk groups, and resilience against hesitancy. The Middle East is shaped by travel, pilgrimage, expatriate populations, and uneven access across health systems. Africa faces substantial opportunities to integrate adult vaccination with primary care, maternal services, occupational health, and outbreak preparedness. Asia-Pacific reflects wide variation, with advanced delivery infrastructure in some economies and major access, awareness, and logistics challenges in others.

Group-Level Signals: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members benefit from regional cooperation but require approaches that accommodate substantial differences in financing, demographics, and delivery capacity. BRICS countries collectively highlight the importance of integrating adult immunization with large public-health systems, domestic manufacturing capabilities, and diverse population needs. The European Union supports coordination while national schedules and reimbursement arrangements remain important. G7 members generally have mature surveillance and delivery infrastructure, yet still need to address missed adult vaccinations and confidence gaps. GCC countries place particular emphasis on mobile populations, travel-related protection, and digitally enabled healthcare. NATO members have an additional interest in occupational readiness, military health, and continuity of immunization during emergencies.

Country Insights Across Major Adult Vaccine Markets

Australia combines strong primary-care infrastructure with established national immunization programs and a focus on older adults and risk groups. Brazil and Mexico must address geographic and socioeconomic variation while using public-health networks to improve adult access. Canada and the United States rely on a mix of public programs, clinicians, pharmacies, and employer channels, with persistent attention to affordability, convenience, and uptake. China, India, and Indonesia’s broader Asia-Pacific context require scalable delivery models suited to large and diverse populations. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom continue to emphasize aging, chronic disease, seasonal vaccination, and integration with routine care. Russia’s priorities include maintaining adult coverage across a geographically extensive health system and strengthening confidence and access. Across all listed countries, reliable registries, clear recommendations, and convenient delivery remain central to improving uptake.

Practical Priorities for Adult Vaccine Leaders

Industry leaders should align portfolios and services with life-course needs rather than treating adult vaccination as a single segment. Strengthen partnerships with primary-care providers, pharmacies, employers, travel-health services, and public agencies; make eligibility and scheduling easy to understand; and support multilingual, evidence-based communication. Invest in temperature monitoring, resilient distribution, and interoperable records. Use analytics and carefully governed artificial intelligence to find missed opportunities, but measure outcomes by coverage, timeliness, equity, safety, and patient experience. Programs should also incorporate transparent evidence communication and contingency planning for outbreaks, supply interruptions, and changing recommendations.

Research Methodology for the Executive Summary

This executive summary uses the supplied market category, “Adult Vaccines,” together with the specified regional, group, and country coverage. The assessment synthesizes established public-health and healthcare delivery themes, including immunization policy, life-course care, demographic change, access, logistics, digital health, and responsible artificial intelligence. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis. Regional, group, and country observations are presented as qualitative strategic context rather than quantified rankings or commercial projections.

Conclusion: Building More Accessible Adult Immunization Systems

Adult vaccination is increasingly connected to healthy aging, chronic-care management, workforce protection, travel health, and preparedness. Progress will depend on making vaccination visible and convenient at every appropriate healthcare touchpoint, strengthening records and supply systems, and addressing confidence and affordability barriers. Leaders that combine equitable delivery, trusted communication, disciplined data use, and responsible artificial intelligence can help health systems improve protection across the adult life course.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Adult Vaccines Market, by Vaccine Type
7.1. Introduction
7.2. Covid 19
7.2.1. Inactivated
7.2.2. Mrna
7.2.3. Protein Subunit
7.2.4. Viral Vector
7.3. Hepatitis
7.3.1. Combined
7.3.2. Hepatitis A
7.3.3. Hepatitis B
7.4. Herpes Zoster
7.4.1. Shingrix
7.4.2. Zostavax
7.5. Hpv
7.5.1. 9-Valent
7.5.2. Bivalent
7.5.3. Quadrivalent
7.6. Meningococcal
7.6.1. MenACWY
7.6.2. MenB
7.7. Mmr
7.8. Pandemic Influenza
7.9. Pneumococcal
7.9.1. Pcv13
7.9.2. Pcv15
7.9.3. Pcv20
7.9.4. Ppsv23
7.10. Seasonal Influenza
7.11. Tdap
7.11.1. Td
7.11.2. Tdap
7.12. Varicella
8. Adult Vaccines Market, by Vaccine Technology
8.1. Introduction
8.2. Conjugate
8.3. Dna
8.3.1. Gene Encoded
8.3.2. Plasmid Dna
8.4. Inactivated
8.5. Live Attenuated
8.6. Mrna
8.6.1. Nucleoside Modified
8.6.2. Self Amplifying
8.7. Recombinant
8.8. Toxoid
8.8.1. Diphtheria Toxoid
8.8.2. Tetanus Toxoid
8.9. Viral Vector
8.9.1. Non Replicating
8.9.2. Replicating
9. Adult Vaccines Market, by Route Of Administration
9.1. Introduction
9.2. Intradermal
9.3. Intramuscular
9.4. Intranasal
9.5. Oral
9.6. Subcutaneous
10. Adult Vaccines Market, by Age Group
10.1. Introduction
10.2. 18 To 30
10.3. 31 To 45
10.4. 46 To 60
10.5. 61 And Above
11. Adult Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Online Pharmacies
11.5. Public Health Centers
11.6. Retail Pharmacies
12. Adult Vaccines Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Adult Vaccines Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Adult Vaccines Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bavarian Nordic A/S
16.2. CSL Limited
16.3. GlaxoSmithKline plc
16.4. Johnson & Johnson
16.5. Merck & Co., Inc.
16.6. Moderna, Inc.
16.7. Novavax, Inc.
16.8. Novavax, Inc.
16.9. Pfizer Inc.
16.10. Sanofi S.A.
16.11. Takeda Pharmaceutical Company Ltd.
16.12. Valneva SE
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Adult Vaccines Market, Years Considered for the Study
FIGURE 2. Global Adult Vaccines Market, Research Design
FIGURE 3. Global Adult Vaccines Market, Research Framework
FIGURE 4. Global Adult Vaccines Market, Data Triangulation
FIGURE 5. Global Adult Vaccines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Adult Vaccines Market Size, by Vaccine Type, 2025 vs 2032 (%)
FIGURE 7. Global Adult Vaccines Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Adult Vaccines Market Size, by Vaccine Technology, 2025 vs 2032 (%)
FIGURE 9. Global Adult Vaccines Market Size, by Vaccine Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Adult Vaccines Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Adult Vaccines Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Adult Vaccines Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Adult Vaccines Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Adult Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Adult Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Adult Vaccines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Adult Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Adult Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Adult Vaccines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Adult Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Adult Vaccines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Adult Vaccines Market Segmentation & Coverage
TABLE 2. Global Adult Vaccines Market Size, 2017-2032 (USD Million)
TABLE 3. Global Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 4. Global Covid 19 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Covid 19 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Covid 19 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Protein Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Protein Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Protein Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Hepatitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Hepatitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Hepatitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Combined Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Combined Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Combined Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Hepatitis A Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Hepatitis A Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Hepatitis A Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Hepatitis B Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Hepatitis B Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Hepatitis B Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Herpes Zoster Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Herpes Zoster Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Herpes Zoster Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Shingrix Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Shingrix Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Shingrix Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Zostavax Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Zostavax Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Zostavax Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hpv Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hpv Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hpv Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global 9-Valent Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global 9-Valent Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global 9-Valent Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Bivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Bivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Bivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Meningococcal Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Meningococcal Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Meningococcal Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global MenACWY Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global MenACWY Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global MenACWY Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global MenB Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global MenB Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global MenB Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Mmr Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Mmr Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Mmr Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Pandemic Influenza Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Pandemic Influenza Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Pandemic Influenza Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Pneumococcal Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Pneumococcal Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Pneumococcal Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Pcv13 Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Pcv13 Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Pcv13 Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Pcv15 Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Pcv15 Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Pcv15 Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Pcv20 Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Pcv20 Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Pcv20 Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Ppsv23 Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Ppsv23 Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Ppsv23 Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Seasonal Influenza Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Seasonal Influenza Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Seasonal Influenza Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Tdap Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Tdap Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Tdap Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Td Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Td Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Td Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Tdap Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Tdap Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Tdap Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Varicella Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Varicella Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Varicella Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 98. Global Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Dna Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Dna Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Dna Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Gene Encoded Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Gene Encoded Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Gene Encoded Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Plasmid Dna Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Plasmid Dna Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Plasmid Dna Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Nucleoside Modified Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Nucleoside Modified Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Nucleoside Modified Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Self Amplifying Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Self Amplifying Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Self Amplifying Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Toxoid Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Toxoid Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Toxoid Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Diphtheria Toxoid Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Diphtheria Toxoid Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Diphtheria Toxoid Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Tetanus Toxoid Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Tetanus Toxoid Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Tetanus Toxoid Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Non Replicating Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Non Replicating Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Non Replicating Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Replicating Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Replicating Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Replicating Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 147. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 156. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 160. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 162. Global Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 163. Global 18 To 30 Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global 18 To 30 Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global 18 To 30 Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global 31 To 45 Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Global 31 To 45 Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. Global 31 To 45 Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. Global 46 To 60 Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Global 46 To 60 Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. Global 46 To 60 Market Size, by Country, 2017-2032 (USD Million)
TABLE 172. Global 61 And Above Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Global 61 And Above Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. Global 61 And Above Market Size, by Country, 2017-2032 (USD Million)
TABLE 175. Global Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 180. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. Global Public Health Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Global Public Health Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. Global Public Health Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 188. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 189. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 191. Global Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 192. Asia-Pacific Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Asia-Pacific Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 194. Asia-Pacific Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 195. Asia-Pacific Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 196. Asia-Pacific Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 197. Asia-Pacific Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 198. Asia-Pacific Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 199. Asia-Pacific Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 200. Asia-Pacific Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 201. Asia-Pacific Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 202. Asia-Pacific Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 203. Asia-Pacific Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 204. Asia-Pacific Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 205. Asia-Pacific Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 206. Asia-Pacific Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Asia-Pacific Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 208. Asia-Pacific Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. North America Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 210. North America Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 211. North America Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 212. North America Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 213. North America Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 214. North America Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 215. North America Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 216. North America Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 217. North America Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 218. North America Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 219. North America Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 220. North America Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 221. North America Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 222. North America Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 223. North America Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. North America Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 225. North America Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Latin America Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Latin America Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 228. Latin America Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 229. Latin America Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 230. Latin America Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 231. Latin America Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 232. Latin America Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 233. Latin America Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 234. Latin America Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 235. Latin America Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 236. Latin America Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 237. Latin America Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 238. Latin America Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 239. Latin America Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 240. Latin America Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. Latin America Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 242. Latin America Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. Europe Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 244. Europe Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 245. Europe Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 246. Europe Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 247. Europe Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 248. Europe Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 249. Europe Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 250. Europe Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 251. Europe Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 252. Europe Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 253. Europe Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 254. Europe Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 255. Europe Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 256. Europe Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 257. Europe Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. Europe Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 259. Europe Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. Middle East Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 261. Middle East Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 262. Middle East Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 263. Middle East Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 264. Middle East Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 265. Middle East Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 266. Middle East Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 267. Middle East Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 268. Middle East Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 269. Middle East Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 270. Middle East Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 271. Middle East Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 272. Middle East Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 273. Middle East Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 274. Middle East Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 275. Middle East Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 276. Middle East Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Africa Adult Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 278. Africa Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 279. Africa Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 280. Africa Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 281. Africa Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 282. Africa Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 283. Africa Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 284. Africa Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 285. Africa Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 286. Africa Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 287. Africa Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 288. Africa Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 289. Africa Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 290. Africa Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 291. Africa Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 292. Africa Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 293. Africa Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 294. Global Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 295. ASEAN Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. ASEAN Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 297. ASEAN Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 298. ASEAN Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 299. ASEAN Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 300. ASEAN Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 301. ASEAN Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 302. ASEAN Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 303. ASEAN Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 304. ASEAN Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 305. ASEAN Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 306. ASEAN Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 307. ASEAN Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 308. ASEAN Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 309. ASEAN Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 310. ASEAN Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 311. ASEAN Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. GCC Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 313. GCC Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 314. GCC Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 315. GCC Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 316. GCC Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 317. GCC Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 318. GCC Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 319. GCC Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 320. GCC Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 321. GCC Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 322. GCC Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 323. GCC Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 324. GCC Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 325. GCC Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 326. GCC Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 327. GCC Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 328. GCC Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 329. European Union Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 330. European Union Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 331. European Union Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 332. European Union Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 333. European Union Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 334. European Union Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 335. European Union Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 336. European Union Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 337. European Union Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 338. European Union Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 339. European Union Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 340. European Union Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 341. European Union Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 342. European Union Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 343. European Union Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 344. European Union Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 345. European Union Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 346. BRICS Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 347. BRICS Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 348. BRICS Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 349. BRICS Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 350. BRICS Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 351. BRICS Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 352. BRICS Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 353. BRICS Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 354. BRICS Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 355. BRICS Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 356. BRICS Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 357. BRICS Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 358. BRICS Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 359. BRICS Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 360. BRICS Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 361. BRICS Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 362. BRICS Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 363. G7 Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 364. G7 Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 365. G7 Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 366. G7 Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 367. G7 Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 368. G7 Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 369. G7 Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 370. G7 Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 371. G7 Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 372. G7 Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 373. G7 Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 374. G7 Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 375. G7 Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 376. G7 Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 377. G7 Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 378. G7 Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 379. G7 Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 380. NATO Adult Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 381. NATO Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 382. NATO Adult Vaccines Market Size, by Covid 19, 2017-2032 (USD Million)
TABLE 383. NATO Adult Vaccines Market Size, by Hepatitis, 2017-2032 (USD Million)
TABLE 384. NATO Adult Vaccines Market Size, by Herpes Zoster, 2017-2032 (USD Million)
TABLE 385. NATO Adult Vaccines Market Size, by Hpv, 2017-2032 (USD Million)
TABLE 386. NATO Adult Vaccines Market Size, by Meningococcal, 2017-2032 (USD Million)
TABLE 387. NATO Adult Vaccines Market Size, by Pneumococcal, 2017-2032 (USD Million)
TABLE 388. NATO Adult Vaccines Market Size, by Tdap, 2017-2032 (USD Million)
TABLE 389. NATO Adult Vaccines Market Size, by Vaccine Technology, 2017-2032 (USD Million)
TABLE 390. NATO Adult Vaccines Market Size, by Dna, 2017-2032 (USD Million)
TABLE 391. NATO Adult Vaccines Market Size, by Mrna, 2017-2032 (USD Million)
TABLE 392. NATO Adult Vaccines Market Size, by Toxoid, 2017-2032 (USD Million)
TABLE 393. NATO Adult Vaccines Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 394. NATO Adult Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 395. NATO Adult Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 396. NATO Adult Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 397. Global Adult Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 398. United States Adult Vaccines Market Size, 2017-2032 (USD Million)
TABLE 399. United States Adult Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 400. United Sta

Companies Mentioned

  • Bavarian Nordic A/S
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Valneva SE

Related Topics

Related Reports

Adult Vaccines Market Report by Disease wise and Countries and Companies Analysis 2026-2034 - Product Image

Adult Vaccines Market Report by Disease wise and Countries and Companies Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Adult Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Adult Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Adult Vaccines Market Report 2026 - Product Image

Adult Vaccines Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Adult Vaccines Market - Global Strategic Business Report - Product Image

Adult Vaccines Market - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Adult Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Adult Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.